期刊文献+

中国健康志愿者口服奈必洛尔的群体药代动力学模型的建立 被引量:3

Establishment of population pharmacokinetics model of nebivolol in Chinese healthy volunteers
下载PDF
导出
摘要 建立中国健康志愿者口服奈必洛尔的群体药代动力学模型(PPK),评价奈必洛尔临床药代动力学的显著影响因素。收集25名健康志愿者的临床资料,进行单剂量和多剂量给药试验,志愿者口服奈必洛尔5 mg后,以LC-MS/MS法测定奈必洛尔血药浓度,用非线性混合效应模型法(NONMEM)建立奈必洛尔PPK模型,并用自举法进行验证。结果表明:奈必洛尔在健康志愿者体内的药代动力学可用二房室模型描述,个体间变异符合乘法模型。奈必洛尔中央室分布容积及清除率的群体典型值分别为1.84×103L和7.68×102L/h。体重、舒张压、血尿素氮和代谢表型均对奈必洛尔的PPK参数有显著影响。自举法的验证结果与模型计算值相符。所建立的PPK模型可以较好的解释奈必洛尔药代动力学个体差异显著的原因,为奈必洛尔在中国人群中的临床合理用药提供药代动力学参考。 To establish population pharmacokinetics model of nebivolol given by oral route in Chinese healthy volunteers using nonlinear mixed effect model(NONMEM),thus evaluating the factors that could influence clinical pharmacokinetics of nebivolol.Clinical data from 25 healthy volunteers were collected and the experiments included single-dose and multiple-dose administration.Volunteers were given 5 mg nebivolol orally and plasma concentrations of the drug were determined by LC-MS/MS.The population pharmacokinetic modeling was performed with NONMEM program and estimated by bootstrap procedure.The results showed that two-compartment model had fit for nebivolol pharmacokinetics.Inter-individual variability was described by multiplicative model.Typical values of central volume of distribution and clearance were 1.84×103 L and 7.68×102 L/h.The population pharmacokinetic parameters were mainly influenced by body weight,diastolic blood pressure,blood urea nitrogen and phenotype.The parameters estimated from nonparametric bootstrap procedure were comparable to those from NONMEM.The established population pharmacokinetics model could explain the reasons for the plasma concentration of individual variations of nebivolol,which could be used to guide clinical administration to Chinese people.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2012年第3期253-259,共7页 Journal of China Pharmaceutical University
关键词 奈必洛尔 群体药代动力学 中国健康志愿者 非线性混合效应模型 nebivolol population pharmacokinetics Chinese healthy volunteers nonlinear mixed effect model
  • 相关文献

参考文献2

二级参考文献39

  • 1王守春,韩丽萍,司凯英,栾杰.肾移植术后服用环孢素A2h血药浓度峰值监测及治疗窗浓度探讨[J].中国药房,2006,17(3):199-201. 被引量:16
  • 2张弨,翟所迪.群体药动学在治疗药物监测中的应用[J].临床药物治疗杂志,2006,4(1):45-50. 被引量:9
  • 3付培鑫,王传跃.精神药物的治疗药物监测[J].中国医院用药评价与分析,2007,7(3):176-179. 被引量:15
  • 4张峻,杨龙,唐薇,张瑛,周琼,宋贤.大剂量甲氨蝶呤在急性淋巴细胞白血病患儿中的群体药动学[J].中国医院药学杂志,2007,27(8):1061-1065. 被引量:12
  • 5Dars MA, Doevendans PA, Bekkers BC. , et al. Nebivolol: a thirdgeneration 13 -blocker that augments vascular nitric oxide release endothelial 132 Adrenergic receptor-mediated nitric oxide produc tion [ J ]. Circulation, 2000,102 ( 2 ) :677 - 684.
  • 6Simon G, Johnson ML. Comparison of antihypertensive and β1- adrenoreceptor antagonist effect of nebivolol and atenolol in eddential hypertension [ J ]. Clin Exp Hypertens, 1993,15 ( 3 ) : 501 - 509.
  • 7Van Peer A, Snoeck E, Woestenborghs R. Clinical pharmacokinetics of nebivolol. A review [ J ]. Drug Invest, 1991,3 ( Suppl 1 ) : 25 -30.
  • 8Himmelmann A, Hedner T, Snoeck E, et al. Haemodynamie effects and pharmacokinetics of oral d - and 1 -nebivolol in hypertensive patients[J]. Eur J Clin Pharmacol,1996,51( 3/4 ) :259 - 264.
  • 9Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects [ J ]. Eur J Clin Pharmacol, 1997,5 ( 6 ) : 493 - 498.
  • 10Charles L, Stephan O, Andrew S, et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: Drug-drug interaction studies[ J/OL]. (2010-05-20) [2010-11- 23 ]. http://jcp, sagepub, com/content /early/2010/05/19/ 0091270010370846. long.

共引文献19

同被引文献19

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部